Bridgebio Pharma Inc - SCHEDULE 13G/A Filing Summary

This filing details changes in beneficial ownership for Bridgebio Pharma Inc. The Vanguard Group, Inc. has reported a change in its holdings, with a previous value of $1,289,827,235.0 and 0.0 shares. The filing indicates that Vanguard, including its investment companies and managed accounts, has the right to receive or direct the receipt of dividends and proceeds from the sale of the securities. However, due to an internal realignment on January 12, 2026, certain subsidiaries and business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately. Consequently, The Vanguard Group, Inc. no longer holds or is deemed to hold beneficial ownership over securities owned by these disaggregated entities. The filing asserts that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing the control of the issuer.